Enlaza Therapeutics, Inc. — Form D
Enlaza Therapeutics, Inc. of LA JOLLA, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-10-13. The offering totals $312K. Industry: Pharmaceuticals.
Offering
- Filed: 2022-10-13
- Form: D
- Accession: 0001852950-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $312K
- Remaining: $312K
- Investors: 1
- Date of first sale: 2022-10-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-461697
Issuer
- Name: Enlaza Therapeutics, Inc.
- CIK: 0001852950
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 11099 NORTH TORREY PINES ROAD, STE. 280, LA JOLLA, CA, 92037
- Phone: 858-348-2180
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Shelley Chu | Director | Lexington, MA |
| Tighe Reardon | Executive Officer | La Jolla, CA |
| Stephen Squinto | Director | Stamford, CT |
| Marcos Milla | Director | La Jolla, CA |
| Jay Lichter | Director | La Jolla, CA |
| Sergio Duron | Director | La Jolla, CA |
| Sergio Duron | Executive Officer | La Jolla, CA |
| James Topper | Director | La Jolla, CA |
| Sanford Madigan | Executive Officer | La Jolla, CA |
Other filings by this issuer (7)
More